Back to top

Why EVENITY®
first after fracture?

Thumbnail
Icon logo arch

Active-ContRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture

The study compared the effectiveness of a treatment regimen starting with EVENITY first, before transitioning to alendronate vs alendronate treatment alone in reducing the risk of fracture.1

Study Design

Fracture Risk Reduction

Bone Mineral Density (BMD)

EVENITY provides rapid and superior improvements in BMD
vs alendronate1

After fracture, EVENITY first for 12 months significantly increased BMD at lumbar spine, total hip and femoral neck, at Month 12 compared with alendronate3

Significant differences in BMD were maintained through Month 36 upon transition/continuation to alendronate1

Efficacy of EVENITY in women with severe osteoporosis at high risk of fracture

The ARCH study aimed to discover the impact of EVENITY on postmenopausal women with a previous fragility fracture.2,3
Watch our short film to discover its findings. 

View Baseline Characteristics

Baseline characteristics

Characteristics3 EVENITY (n=2,046)* Alendronate (n=2,047)*
Age, years 74.4 ± 7.5 74.2 ± 7.5
BMD T-score
Femoral neck -2.89 ± 0.49 -2.90 ± 0.50
Lumbar spine -2.94 ± 1.25 -2.99 ± 1.24
Total hip -2.78 ± 0.68 -2.81 ± 0.67
Previous osteoporotic fracture, n (%) 2,022 (98.8) 2,029 (99.1)
Prevalent vertebral fracture, n (%) 1,969 (96.2) 1,964 (95.9)
Grade of most severe vertebral fracture, n (%)
Mild 68 (3.3) 73 (3.6)
Moderate 532 (26.0) 570 (27.8)
Severe 1,369 (66.9) 1,321 (64.5)
Previous non-vertebral fracture, n (%) 767 (37.5) 770 (37.6)
Previous hip fracture, n (%) 175 (8.6) 179 (8.7)
10-year risk of major osteoporotic fracture by FRAX®§ 20.2 ± 10.2 20.0 ± 10.1
BMI, kg/m2 25.46 ± 4.41 25.36 ± 4.42
Median 25-hydroxyvitamin D, ng/mL (IQR) 28.4 (24.0-34.8) 27.6 (24.0-34.2)
Median serum P1NP, µg/L (IQR) 50.6 (37.5-64.7) 44.7 (32.7-64.4)
Median serum β-CTX, ng/L (IQR) 276.0 (166.0-407.0) 230 (137.0-388.0)

*Number of patients who were randomly assigned to the 12-month double-blind period of the study. Assessed using the Genant grading scale. Excludes pathologic or high-trauma hip fracture. FRAX®§ is a registered trademark of Professor J.A. Kanis, University of Sheffield. This indicates the 10-year probability of major osteoporotic fracture, expressed as % and calculated with BMD. Data shown are for the 266 patients (alendronate n=128; EVENITY n=138) who enrolled in the biomarker sub-study and who had measurements of bone turnover markers both at baseline and at one or more visits after baseline.

View References
  1. EVENITY  SmPC.
  2. Clinicaltrials.gov. Available at: www.clinicaltrials.gov/ct2/show/NCT01631214.
  3. Saag KG, et al. N Eng J Med 2017;377:1417-1427.
  4. Data on file. CSR20110142. Page 276 – Table 14-2.7.